Purpose Cisplatin is widely used but highly ototoxic. Effects of cumulative cisplatin dose on
hearing loss have not been comprehensively evaluated in survivors of adult-onset cancer …

Objective: To determine whether abnormalities in routine blood tests were associated with
increased susceptibility to hearing loss induced by cisplatin chemotherapy. Design: Cohort …

Purpose To determine the auditory toxicity associated with dose-and schedule-intensive
cisplatin/gemcitabine chemotherapy in non–small-cell lung carcinoma patients. Patients and …

The role and optimal use of audiometry in monitoring for cisplatin ototoxicity are
incompletely defined. Audiograms were obtained from 217 patients before treatment with …

This study evaluates the degree and relevance of persisting ototoxicity after cisplatin-based
standard-dose chemotherapy for testicular cancer, with emphasis on identification of …

Cisplatin has been associated with hearing damage. It is usually irreversible, bilateral, and
characterized by high-frequency sensorineural hearing loss. This study was carried out to …

PURPOSE: To investigate the risk of sensorineural hearing loss (SNHL) in patients with
head-and-neck cancer and treated with radiation therapy (RT) or concomitant cisplatin …

Objective: To describe hearing changes in a group of 28 children (age range, 8‐180 mo)
undergoing protocol‐based cisplatin therapy. Methods: Conventional, play audiometry …

Cisplatin, an effective antineoplastic drug used in the treatment of many cancers, has
ototoxic potential, thus placing cancer patients, receiving this treatment, at risk of hearing …

Purpose We present a new ototoxicity grading system that has clearly defined and frequency-
specific audiometric criteria. The purpose of this study was to validate this grading system by …